Table 9. Selected Pharmacologic Intervention Trials Using CHD Mortality and/or Mortality as Endpoints.

Subjects Study Characterization
Study N Age Design Randomized Duration (Y) TC* Reduction (%) Comments
Lipid Research Clinics Study 3806 male Middle-Aged Double Blinded Cholestyramine Yes 7 9 19% reduction in CHD risk 1 prevention
Helsinki Heart 4081 male Middle-Aged Double Blinded Gemfibrozil Yes 5 11 34% reduction in CHD risk 1 prevention
Coronary Drug Project 8341 Middle-Aged Double Blinded Niacin Yes 5 10 20% reduction in CHD risk 11% reduction in all-cause mortality 2 prevention
4S Study 4444 male, female Middle-Aged Double Blinded Simvastatin Yes 5 20

34% reduction in CHD risk 0% decrease in total mortality

2 prevention; 37% decrease in stroke
WOSCOPS Study 6505 Middle-Aged Double Blinded Pravastatin Yes 5 20 31% reduction in CHD risk 22% reduction in total mortality 1¡ prevention
CARE 4159 male, female CHD > 50 Double Blinded Pravastatin Yes 5 20 24% reduction in CHD risk 31% reduction in stroke, post -MI patients
AFCAPS/TEXCAPS 6605 male, female > 45 Double Blinded Lovastatin Yes 5 22 36% reduction in CHD endpoints 1° prevention
LIPID 9103 male, female Aged Elderly Double Blinded Pravastatin Yes 5 19 23%,24%,and 20% reduction in total, CHD, and stroke mortality 2° prevention